Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

On Monday, 10X Genomics Inc (TXG) stock saw a decline, ending the day at $13.18 which represents a decrease of $-0.16 or -1.20% from the prior close of $13.34. The stock opened at $13.34 and touched a ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), retaining the price target ...

Fintel reports that on November 7, 2024, Leerink Partners upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Market ...

Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...